Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 205, Issue 10, Pages 1589-1592Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jis240
Keywords
-
Categories
Funding
- CDC [TS-1363]
- Pfizer
Ask authors/readers for more resources
Pneumococcal pneumonia is concentrated among the elderly. Using a decision analytic model, we projected the future incidence of pneumococcal pneumonia and associated healthcare utilization and costs accounting for an aging US population. Between 2004 and 2040, as the population increases by 38%, pneumococcal pneumonia hospitalizations will increase by 96% (from 401 000 to 790 000), because population growth is fastest in older age groups experiencing the highest rates of pneumococcal disease. Absent intervention, the total cost of pneumococcal pneumonia will increase by $2.5 billion annually, and the demand for healthcare services for pneumococcal pneumonia, especially inpatient capacity, will double in coming decades.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available